I. MODIFIED AGREEMENTS

Company* (Country; Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)

Abgenix Inc. (ABGX)

Immunex Corp. (subsidiary of Amgen Inc.; AMGN)

Amended terms of July 2000 deal giving Immunex authority over development and marketing

Abgenix will assume manufacturing responsibility and will be advanced $60M to fund its share of development costs; the companies continue to share costs and any profits (10/14)

BioTransplant Inc. (OTC BB: BTRNQ)

Miltenyi Biotec GmbH* (Germany)

Miltenyi will pay lower rates for Eligix cell-separation systems

Miltenyi now will pay $175,000 up front and royalties of 4% to 8% percent on sales (10/3)

Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT)

Genzyme Corp. (GENZ)

Restructured agreement with CAT increasing its financial contribution to joint work on anti-TNF-beta antibodies and  Genzyme investing $37.7M in CAT shares

CAT is now committed to fund 50% of the development costs over the next two years, significantly increasing its share of the profits (9/22)

Discovery Partners International Inc. (DSCO)

Inspire Pharmaceuticals Inc. (ISPH)

Expanded agreement for Discovery Partners to optimize compounds in the P2 receptor family

Financial terms were not disclosed (10/20)

Inpharmatica Ltd.* (UK)

Serono SA (Switzerland; NYSE:SRA)

Extended collaboration for Inpharmatica to develop and apply its computational chemogenomics system, PharmaCarta, to identifying proteins

Financial terms were not disclosed (8/28)

OncoGenex Technologies Inc.* (Canada)

Isis Pharmaceuticals Inc. (ISIS)

Expanded partnership to include the development of a second-generation antisense inhibitor

OGX-225 targets both insulin-like growth factor-binding protein-2 and -5, molecules involved in the development of metastatic disease in hormone-regulated tumors such as prostate and breast cancers (9/9)

Protein Design Labs Inc. (PDLI)

Genentech Inc. (NYSE:DNA)

Extended agreement for each company to obtain nonexclusive licenses under the other company's  relevant antibody humanization patents

Genentech and PDL can obtain nonexclusive licenses for a fee of up to about $1M per antibody; the deal is extended for five years (9/19)

Targeted Genetics Corp. (TGEN)

GenVec Inc. (GNVC)

Expanded agreement under which Targeted Genetics manufactures TNFerade for GenVec

Targeted Genetics will manufacture product for late-stage trials of the cancer drug; terms were not disclosed (10/14)

Transgenomic Inc. (TBIO)

Geron Corp. (GERN)

Transgenomic will provide an additional supply of nucleic  acid building-block compounds for use in syntheis of Geron cancer drug GRN163L

Extension of nonexclusive agreement; financial terms were not disclosed (9/25)

II. TERMINATED AGREEMENTS

BioCryst Pharmaceuticals Inc. (BCRX)

3-Dimensional Pharmaceuticals Inc.*

Terminated collaboration for enzyme inhibitors of the cascade system

3-Dimensional's DirectedDiversity technology was to discover compounds directed at the serine proteases identified by BioCryst; BioCryst ended the deal in order to free up funds (8/27)

Epoch Biosciences Inc.(EBIO) 

Amersham Biosciences (unit of Amersham plc; UK; NYSE:AHM)

Epoch terminated a licensing and distribution agreement on its MGB Eclipse Probe Systems for SNPs

Epoch said Amersham failed to meet sales minimums called for under worldwide sales and distribution partnership established in 2002 (10/6)

Vyrex Corp. (OTC BB:VYRX)

The Immune Response Corp. (IMNR)

Vyrex decided not to extend the collaboration to develop Vyrex's prodrug of propofol

Vyrex said it is seeking a new partner for development (10/21)

Notes:

# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.